M Cózar Santiago, J García Garzón, A Esteban Hurtado, J Pastor Peiro, J Ferrer Rebolleda
{"title":"前列腺癌根治性前列腺切除术后PSA低于1 ng/mL诊断为前列腺癌患者的F-PSMA PET/CT阴性研究对补救性放疗预后的临床价值[18F]。","authors":"M Cózar Santiago, J García Garzón, A Esteban Hurtado, J Pastor Peiro, J Ferrer Rebolleda","doi":"10.1016/j.remnie.2025.500071","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the clinical value of [<sup>18</sup>F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.</p><p><strong>Method: </strong>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17-1.0 ng/mL)] who were referred for an [<sup>18</sup>F]F-PSMA -PET/CT study. The [<sup>18</sup>F]F-PSMA -PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</p><p><strong>Results: </strong>54.7% (29/53) of the patients with a negative [<sup>18</sup>F]F-PSMA -PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study. 45.3% (24/53) of patients with negative [<sup>18</sup>F]F-PSMA -PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study. Our series confirmed 42 (42.85%) [<sup>18</sup>F]F-PSMA -PET/CT false negatives cases.</p><p><strong>Conclusion: </strong>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [<sup>18</sup>F]F-PSMA -PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</p>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":" ","pages":"500071"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical value of a negative [<sup>18</sup>F]F-PSMA PET/CT study in patients diagnosed with prostate cancer treated with prostatectomy with PSA rising below 1 ng/mL after radical prostatectomy, on the outcome of salvage radiotherapy.\",\"authors\":\"M Cózar Santiago, J García Garzón, A Esteban Hurtado, J Pastor Peiro, J Ferrer Rebolleda\",\"doi\":\"10.1016/j.remnie.2025.500071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess the clinical value of [<sup>18</sup>F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.</p><p><strong>Method: </strong>We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17-1.0 ng/mL)] who were referred for an [<sup>18</sup>F]F-PSMA -PET/CT study. The [<sup>18</sup>F]F-PSMA -PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.</p><p><strong>Results: </strong>54.7% (29/53) of the patients with a negative [<sup>18</sup>F]F-PSMA -PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study. 45.3% (24/53) of patients with negative [<sup>18</sup>F]F-PSMA -PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [<sup>18</sup>F]F-PSMA -PET/CT follow-up study. Our series confirmed 42 (42.85%) [<sup>18</sup>F]F-PSMA -PET/CT false negatives cases.</p><p><strong>Conclusion: </strong>Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [<sup>18</sup>F]F-PSMA -PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.</p>\",\"PeriodicalId\":94197,\"journal\":{\"name\":\"Revista espanola de medicina nuclear e imagen molecular\",\"volume\":\" \",\"pages\":\"500071\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista espanola de medicina nuclear e imagen molecular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.remnie.2025.500071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de medicina nuclear e imagen molecular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.remnie.2025.500071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical value of a negative [18F]F-PSMA PET/CT study in patients diagnosed with prostate cancer treated with prostatectomy with PSA rising below 1 ng/mL after radical prostatectomy, on the outcome of salvage radiotherapy.
Objective: To assess the clinical value of [18F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.
Method: We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.17-1.0 ng/mL)] who were referred for an [18F]F-PSMA -PET/CT study. The [18F]F-PSMA -PET/CT scan was negative in 53/98 patients (54.09%). Differences were analysed between those patients who were or were not candidates for pelvic salvage radiotherapy (PSRT) decided upon multidisciplinary committee and patient consent, with a minimum follow-up time for 1 year. Response to treatment was defined as a 50% reduction in PSA levels. Recurrence was ascertained upon clinical, analytical and imaging follow-up outcomes.
Results: 54.7% (29/53) of the patients with a negative [18F]F-PSMA -PET/CT underwent PSRT. Of these, 93.1% (27/29) patients demonstrated response to treatment (PSMA false negatives). The remaining two patients showed fluctuating PSA levels without detecting disease on the [18F]F-PSMA -PET/CT follow-up study. 45.3% (24/53) of patients with negative [18F]F-PSMA -PET/CT did not undergo PSRT. Of these, progressive PSA elevation was observed in 62.5% (15/24) (PSMA false negatives), localising recurrence on the [18F]F-PSMA -PET/CT follow-up study in 4 patients. The remaining 9 patients (37.5%) showed fluctuating PSA levels without detecting disease on the [18F]F-PSMA -PET/CT follow-up study. Our series confirmed 42 (42.85%) [18F]F-PSMA -PET/CT false negatives cases.
Conclusion: Patients diagnosed with prostate cancer with post-prostatectomy biochemical recurrence and a negative [18F]F-PSMA -PET/CT study are likely to benefit from pelvic salvage radiotherapy, with response seen in 93.1% of our cases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
